Dear Reader,

Most investors have never heard this before …

But there’s a strange, 100-year-old investment secret …

Discovered just before the Great Depression …

That accurately called some of the biggest stock winners we’ve ever seen:

It pinpointed Apple at 50 cents …

Nvidia at 40 cents …

And Netflix at $3.70 …

Today, this investment secret is flashing green on a new set of stocks …

While market uncertainty could send some of America’s most popular stocks crashing down even further in 2026 …

This secret has identified three under-the-radar picks that could thrive in 2026 and beyond.

To learn their names and ticker symbols for FREE …

Click here NOW — before it’s too late.

Sincerely,

Eliza Lasky,
Weiss Advocate

---

Today’s Exclusive News

High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026

Written by Nathan Reiff. Published: 1/19/2026. 

Key Points

• Three biotech names with promising clinical trial data and a history of revenue generation stand out from the broader field for 2026.
• Atai Beckley and Evommune have promising pipelines focused on mental health disorders and inflammatory disease treatments, respectively.
• CorMedix has proven success with its catheter lock products and is expanding beyond the hemodialysis space in compelling ways.

Last year, the biotechnology industry leaned heavily into artificial intelligence (AI), using machine learning to identify drug targets, optimize molecules and predict trial outcomes. Alongside the growing use of technology in drug development, companies focused on obesity, rare diseases and oncology achieved notable commercial progress.

Heading into 2026, the landscape could continue to reward investors willing to accept some risk. Lower interest rates and improved funding conditions may encourage further investment in biotechs, particularly those with clear paths to commercialization. Many of the standout biotech stocks to watch in 2026 have tangible catalysts that could drive growth.

Major Mental Health Disorder Treatment Potential for Atai Beckley

Ticker Revealed: Pre-IPO Access to “Next Elon Musk” Company (Ad)

We’ve found The Next Elon Musk… and what we believe to be the next Tesla. 

It’s already racked up $26 billion in government contracts.

Peter Thiel just bet $1 Billion on it.👉 Unlock the ticker now and get it completely free.

Atai Beckley (NASDAQ: ATAI) develops therapies for mental health disorders, including treatment-resistant depression (TRD) and substance use disorders. The penny stock rose about 175% over the past year, despite rolling off somewhat in the final weeks of 2025. Investor enthusiasm in recent quarters has been buoyed by the completion of the combination of atai Life Sciences and Beckley Psytech and the company’s redomiciliation to the United States.

Investors should watch Atai Beckley’s BPL-003, a nasal spray in development for TRD and alcohol use disorder, which posted positive topline results in a Phase 2b trial last July and additional promising data in November. A Phase 3 trial is expected to begin in the second quarter of 2026. The company’s sizable pipeline also includes other TRD candidates and a potential treatment for social anxiety disorder.

ATAI’s clinical momentum and the size of the potential market are compelling, but the company must manage high R&D expenses and very modest revenue. For that reason, 2026 may be a make-or-break year. Investors willing to take a chance on a promising TRD treatment could see substantial returns if trials and commercialization proceed as hoped.

Hemodialysis Wins and Broadening Into New Spaces Could Drive CorMedix This Year

We’ve previously highlighted CorMedix Inc. (NASDAQ: CRMD) for its strength in the catheter lock market. Its DefenCath product has shown potential to reduce catheter-related infections and hospitalizations among dialysis patients. Another potential catalyst is REZZAYO, a treatment for candidemia that is currently in a Phase 3 trial with data expected next quarter.

CorMedix is also expanding beyond its core hemodialysis franchise, most recently acquiring Melinta Therapeutics, known for fungal and bacterial infection treatments. Melinta’s portfolio contributed roughly $13 million to CorMedix’s sales in September alone, and investors may see an additional boost when the company reports full-year results.

The firm’s strong third-quarter 2025 results—including meaningful top- and bottom-line gains—and a solid cash position should help provide a cushion amid uncertainty around healthcare reimbursements. That backdrop likely explains why analysts have set a consensus price target for CRMD of $17.86, about 153% above current levels.

Big Potential in the Atopic Dermatitis Space for New Entrant Evommune

Focused on chronic inflammatory diseases, Evommune (NYSE: EVMN) is the newest biotech on our list to go public. The company completed its IPO in November 2025, and shares have climbed nearly 14% in the first two months of trading. Because it is newly public, there is less historical context for Evommune than for some peers, but 2026 could be a breakthrough year.

In the third quarter of 2025—the only quarterly report Evommune has issued since its IPO—the company highlighted key Phase 2 readouts for EVO756 and EVO301, targeting chronic inducible urticaria and certain types of atopic dermatitis, respectively. Top-line results from both trials are expected in early 2026 and could serve as significant catalysts. Atopic dermatitis is one of the most prevalent immune-mediated skin diseases, and patients continue to face limited treatment options.

Evommune has maintained a modest but healthy cash position, reporting about $76 million at the end of the third quarter, and has begun generating revenue through a licensing agreement in Japan. R&D expenses are likely to remain elevated, however. Analysts are optimistic about EVMN, projecting more than 84% upside from current levels.

Thank you for subscribing to Earnings360, a morning newsletter that summarizes quarterly earnings for public companies that trade on U.S. markets.

This email content is a paid sponsorship for Weiss Ratings, a third-party advertiser of Earnings360 and MarketBeat. 

11780 US Highway 1,
Palm Beach Gardens, FL 33408-3080
Would you like to edit your e-mail notification preferences or unsubscribe[/link] from our mailing list?

Copyright © 2025 Weiss Ratings. All rights reserved.
 
 
If you need assistance with your newsletter, don’t hesitate to contact our South Dakota based support team at contact@marketbeat.com.

If you no longer wish to receive email from Earnings360, you can unsubscribe.

© 2006-2026 MarketBeat Media, LLC. 
345 N Reid Place, Sixth Floor, Sioux Falls, South Dakota 57103. United States..

Further Reading: [URGENT!] SpaceX Going Public! – Pre-IPO Action (From Paradigm Press)